The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group
Open accessAbstract
Plasma cell leukemia (PCL) is a rare and aggressive variant of myeloma characterized by the presence of circulating plasma cells. It is classified as either primary PCL occurring at diagnosis or as secondary PCL in patients with relapsed/refractory myeloma. Primary PCL is a distinct clinic-pathological entity with different cytogenetic and molecular findings. The clinical course is aggressive with short remissions and survival duration. The diagnosis is based upon the percentage (⩾20%) and absolute number (⩾2 × 109/l) of plasma cells in the peripheral blood. It is proposed that the thresholds for diagnosis be re-examined and consensus recommendations are made for diagnosis, as well as, response and progression criteria. Induction therapy needs to begin promptly and have high clinical activity leading to rapid disease control in an effort to minimize the risk of early death. Intensive chemotherapy regimens and bortezomib-based regimens are recommended followed by high-dose therapy with autologous stem cell transplantation if feasible. Allogeneic transplantation can be considered in younger patients. Prospective multicenter studies are required to provide revised definitions and better understanding of the pathogenesis of PCL.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Döhner, H., Estey, E. H., Amadori, S., Appelbaum, F. R., Büchner, T., Burnett, A. K., Dombret, H., Fenaux, P., Grimwade, D., Larson, R. A., et al. (2010) · Blood · doi:10.1182/blood-2009-07-235358 · Cited by 3,373
International uniform response criteria for multiple myeloma
Durie, B. G. M., Harousseau, J.-L., Miguel, J. S., Bladé, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404284 · Cited by 2,632
Self-citationThe International Myeloma Working Group (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04355.x · Cited by 2,321
BladÉ, J., Samson, D., Reece, D., Apperley, J., BJÖrkstrand, B., Gahrton, G., Gertz, M., Giralt, S., Jagannath, S., Vesole, D., et al. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00930.x · Cited by 1,519
Self-citationLenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma
Attal, M., Lauwers-Cances, V., Marit, G., Caillot, D., Moreau, P., Facon, T., Stoppa, A. M., Hulin, C., Benboubker, L., Garderet, L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114138 · Cited by 1,155
Self-citationLenalidomide after Stem-Cell Transplantation for Multiple Myeloma
McCarthy, P. L., Owzar, K., Hofmeister, C. C., Hurd, D. D., Hassoun, H., Richardson, P. G., Giralt, S., Stadtmauer, E. A., Weisdorf, D. J., Vij, R., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114083 · Cited by 1,147
Self-citationMultiple myeloma; a review of 26 cases.
Harnagel, E. E., Kleinberg, I., Kahlstrom, S. C., & Rhudy, F. V. (1957) · PubMed · Cited by 682
Multiple Myeloma: Review of 869 Cases
Kyle, R. A. (1975) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(25)00115-6 · Cited by 640
Self-citationRosiñol, L., Oriol, A., Teruel, A. I., Hernández, D., López-Jiménez, J., de la Rubia, J., Granell, M., Besalduch, J., Palomera, L., González, Y., et al. (2012) · Blood · doi:10.1182/blood-2012-02-408922 · Cited by 486
Self-citationDimopoulos, M., Kyle, R., Fermand, J.-P., Rajkumar, S. V., San Miguel, J., Chanan-Khan, A., Ludwig, H., Joshua, D., Mehta, J., Gertz, M., et al. (2011) · Blood · doi:10.1182/blood-2010-10-299529 · Cited by 454
Self-citationAzab, A. K., Runnels, J. M., Pitsillides, C., Moreau, A.-S., Azab, F., Leleu, X., Jia, X., Wright, R., Ospina, B., Carlson, A. L., et al. (2009) · Blood · doi:10.1182/blood-2008-10-186668 · Cited by 428
Self-citationEgan, J. B., Shi, C.-X., Tembe, W., Christoforides, A., Kurdoglu, A., Sinari, S., Middha, S., Asmann, Y., Schmidt, J., Braggio, E., et al. (2012) · Blood · doi:10.1182/blood-2012-01-405977 · Cited by 404
Self-citationYamamoto, J. F., & Goodman, M. T. (2008) · Cancer Causes & Control · doi:10.1007/s10552-007-9097-2 · Cited by 383
Genetic aberrations and survival in plasma cell leukemia
Tiedemann, R. E., Gonzalez-Paz, N., Kyle, R. A., Santana-Davila, R., Price-Troska, T., Van Wier, S. A., Chng, W. J., Ketterling, R. P., Gertz, M. A., Henderson, K., et al. (2008) · Leukemia · doi:10.1038/leu.2008.4 · Cited by 349
Self-citationMyeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients
Fonseca, R., Blood, E. A., Oken, M. M., Kyle, R. A., Dewald, G. W., Bailey, R. J., Van Wier, S. A., Henderson, K. J., Hoyer, J. D., Harrington, D., et al. (2002) · Blood · doi:10.1182/blood.v99.10.3735 · Cited by 340
Self-citationGarcı́a-Sanz, R., Orfão, A., González, M., Tabernero, M. D., Bladé, J., Moro, M. J., Fernández-Calvo, J., Sanz, M. A., Pérez-Simón, J. A., Rasillo, A., et al. (1999) · Blood · doi:10.1182/blood.v93.3.1032 · Cited by 332
Munshi, N. C., Anderson, K. C., Bergsagel, P. L., Shaughnessy, J., Palumbo, A., Durie, B., Fonseca, R., Stewart, A. K., Harousseau, J.-L., Dimopoulos, M., et al. (2011) · Blood · doi:10.1182/blood-2010-10-300970 · Cited by 311
Self-citationRearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors
Avet-Loiseau, H., Gerson, F., Magrangeas, F., Minvielle, S., Harousseau, J.-L., & Bataille, R. (2001) · Blood · doi:10.1182/blood.v98.10.3082 · Cited by 289
Nowakowski, G. S., Witzig, T. E., Dingli, D., Tracz, M. J., Gertz, M. A., Lacy, M. Q., Lust, J. A., Dispenzieri, A., Greipp, P. R., Kyle, R. A., et al. (2005) · Blood · doi:10.1182/blood-2005-05-1858 · Cited by 245
Self-citationNONSECRETORY MYELOMA, IMMUNOGLOBULIN D MYELOMA, AND PLASMA CELL LEUKEMIA
Bladé, J., & Kyle, R. A. (1999) · Hematology/Oncology Clinics of North America · doi:10.1016/s0889-8588(05)70125-8 · Cited by 215
Self-citationDimopoulos, M. A., Barlogie, B., Smith, T. L., & Alexanian, R. (1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-115-12-931 · Cited by 208
Self-citationPellat-Deceunynck, C., Barillé, S., Jego, G., Puthier, D., Robillard, N., Pineau, D., Rapp, M.-J., Harousseau, J.-L., Amiot, M., & Bataille, R. (1998) · Leukemia · doi:10.1038/sj.leu.2401211 · Cited by 194
Avet-Loiseau, H., Daviet, A., Brigaudeau, C., Callet-Bauchu, E., Terré, C., Lafage-Pochitaloff, M., Désangles, F., Ramond, S., Talmant, P., & Bataille, R. (2001) · Blood · doi:10.1182/blood.v97.3.822 · Cited by 185
Plasma cell leukemia: An evaluation of response to therapy
Noel, P., & Kyle, R. A. (1987) · The American Journal of Medicine · doi:10.1016/0002-9343(87)90942-9 · Cited by 184
Self-citationDimopoulos, M. A., Palumbo, A., Delasalle, K. B., & Alexanian, R. (1994) · British Journal of Haematology · doi:10.1111/j.1365-2141.1994.tb05114.x · Cited by 184
Self-citationBezieau, S., Devilder, M.-C., Avet-Loiseau, H., Mellerin, M.-P., Puthier, D., Pennarun, E., Rapp, M.-J., Harousseau, J.-L., Moisan, J.-P., & Bataille, R. (2001) · Human Mutation · doi:10.1002/humu.1177 · Cited by 180
How I treat plasma cell leukemia
van de Donk, N. W. C. J., Lokhorst, H. M., Anderson, K. C., & Richardson, P. G. G. (2012) · Blood · doi:10.1182/blood-2012-05-408682 · Cited by 157
Self-citationPrognostic Value of Circulating Plasma Cells in Monoclonal Gammopathy of Undetermined Significance
Kumar, S. K., Rajkumar, S. V., Kyle, R. A., Lacy, M. Q., Dispenzieri, A. A., Fonseca, R., Lust, J. A., Gertz, M. A., Greipp, P. R., & Witzig, T. E. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.159 · Cited by 144
Self-citationMitsiades, C. S., McMillin, D. W., Klippel, S., Hideshima, T., Chauhan, D., Richardson, P. G. G., Munshi, N. C., & Anderson, K. C. (2007) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2007.08.007 · Cited by 125
Self-citationDifferential repetitive DNA methylation in multiple myeloma molecular subgroups
Bollati, V., Fabris, S., Pegoraro, V., Ronchetti, D., Mosca, L., Deliliers, G. L., Motta, V., Bertazzi, P. A., Baccarelli, A., & Neri, A. (2009) · Carcinogenesis · doi:10.1093/carcin/bgp149 · Cited by 122
Extravasation and homing mechanisms in multiple myeloma
Broek, I. V., Vanderkerken, K., Camp, B. V., & Riet, I. V. (2007) · Clinical & Experimental Metastasis · doi:10.1007/s10585-007-9108-4 · Cited by 113
Pérez‐Andrés, M., Almeida, J., Martin-Ayuso, M., Moro, M. J., Martín–Núñez, G., Galende, J., Borrego, D., Rodríguez, D., Ortega, F., Hernández‐Rivas, J., et al. (2005) · Leukemia · doi:10.1038/sj.leu.2403647 · Cited by 97
Plasma cell leukemia (PCL): A report on 15 patients
Woodruff, R., Js, M., Paxton, A. M., & Lister, T. A. (1978) · Blood · doi:10.1182/blood.v52.4.839.839 · Cited by 93
Broek, I. V., Broek, I. V., Leleu, X. P., Schots, R., Facon, T., Vanderkerken, K., Camp, B. V., & Riet, I. V. (2006) · PubMed · Cited by 87
Self-citationUsmani, S. Z., Nair, B. P., Qu, P., Hansen, E., Zhang, Q., Petty, N. M., Waheed, S., Shaughnessy, J. D., Alsayed, Y. M., Heuck, C. J., et al. (2012) · Leukemia · doi:10.1038/leu.2012.107 · Cited by 86
Self-citationInterleukin-6 dependence of advanced malignant plasma cell dyscrasias
Zhang, X., Bataille, R., Widjenes, J., & Klein, B. (1992) · Cancer · doi:10.1002/1097-0142(19920315)69:6<1373::aid-cncr2820690612>3.0.co;2-1 · Cited by 83
Kosmo, M. A., & Gale, R. P. (1987) · PubMed · Cited by 76
Frequent upregulation of MYC in plasma cell leukemia
Chiecchio, L., Dagrada, G. P., White, H. E., Towsend, M. R., Protheroe, R. K. M., Cheung, K. L., Stockley, D. M., Orchard, K. H., Cross, N. C. P., Harrison, C. J., et al. (2009) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20670 · Cited by 74
Bortezomib is an efficient agent in plasma cell leukemias
Esparís‐Ogando, A., Alegre, A., Aguado, B., Mateo, G., Gutiérrez, N., Bladé, J., Schenkein, D., Pandiella, A., & San Miguel, J. F. (2005) · International Journal of Cancer · doi:10.1002/ijc.20793 · Cited by 70
Self-citationGutierrez, N. C., Hernández, J., García, J., et al. (2001) · Leukemia · doi:10.1038/sj.leu.2402116 · Cited by 59
Johnston, R. E., & Abdalla, S. (2002) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190290006143 · Cited by 55
AMPLIFICATION OF THEC‐MYCONCOGENE IN HUMAN PLASMA‐CELL LEUKEMIA
Sümegi, J., HEDBERG, T., Björkholm, M., Godal, T., Mellstedt, H., NILSSON, M. G., Perlmann, C., & Klein, G. (1985) · International Journal of Cancer · doi:10.1002/ijc.1985.36.3.367 · Cited by 55
Thalidomide treatment down-regulates SDF-1α and CXCR4 expression in multiple myeloma patients
Oliveira, A. M., Maria, D. A., Metzger, M., Linardi, C. C. G., Giorgi, R. R., Moura, F., Martınez, G., Bydlowski, S. P., & Novak, E. M. (2008) · Leukemia Research · doi:10.1016/j.leukres.2008.09.018 · Cited by 39
Chang, H., Yeung, J., Xu, W., Ning, Y., & Patterson, B. J. (2006) · British Journal of Haematology · doi:10.1111/j.1365-2141.2006.06237.x · Cited by 36
Characterization of p16(INK4A) expression in multiple myeloma and plasma cell leukemia.
Urashima, M., Teoh, G., Ogata, A., et al. (1997) · PubMed · Cited by 35
Salvage therapy with lenalidomide and dexamethasone in relapsed primary plasma cell leukemia
Musto, P., Pietrantuono, G., Guariglia, R., Villani, O., Martorelli, M. C., D’Auria, F., Zonno, A., & Lerose, R. (2008) · Leukemia Research · doi:10.1016/j.leukres.2008.03.013 · Cited by 35
Petrucci, M. T., Martini, V., Levi, A., Gallucci, C., Palumbo, G., Bianco, P. D., Torromeo, C., & Foà, R. (2007) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190601007570 · Cited by 33
Effectiveness of lenalidomide (Revlimid) for the treatment of plasma cell leukemia
Benson, D. M., & Smith, M. (2007) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190701361851 · Cited by 30
Guikema, J. E. J., Vellenga, E., Abdulahad, W. H., Hovenga, S., & Bos, N. A. (2004) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04783.x · Cited by 26
Herrick, J. H. (1987) · PubMed · Cited by 25
Pretz, J. L., & Medeiros, B. C. (2009) · American Journal of Hematology · doi:10.1002/ajh.21495 · Cited by 20
Libby, E. N., Quintana, D. D., Moualla, H., Abdul‐Jaleel, M., & Rabinowitz, I. (2010) · American Journal of Hematology · doi:10.1002/ajh.21790 · Cited by 14
Lenalidomide can induce graft versus leukemia effect in primary plasma cell leukemia: A case report
Olivieri, A., Attolico, I., Cimminiello, M., Discepoli, G., & Cifarelli, R. A. (2009) · Leukemia Research · doi:10.1016/j.leukres.2009.04.025 · Cited by 7
Cited by
Diagnosis and Management of Multiple Myeloma: A Review
Cowan, A. J., Green, D. J., Kwok, M., Lee, S., Coffey, D. G., Holmberg, L. A., Tuazon, S., Gopal, A. K., & Libby, E. N. (2022) · JAMA · doi:10.1001/jama.2022.0003 · Cited by 1,029
Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
Dimopoulos, M. A., Moreau, P., Terpos, E., Mateos, M. V., Zweegman, S., Cook, G., Delforge, M., Hájek, R., Schjesvold, F., Cavo, M., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2020.11.014 · Cited by 900
Self-citationMultiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Moreau, P., San Miguel, J., Sonneveld, P., Mateos, M. V., Zamagni, E., Avet-Loiseau, H., Hajek, R., Dimopoulos, M. A., Ludwig, H., Einsele, H., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx096 · Cited by 877
Self-citationEfficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma
Kumar, S., Kaufman, J. L., Gasparetto, C., Mikhael, J., Vij, R., Pegourie, B., Benboubker, L., Facon, T., Amiot, M., Moreau, P., et al. (2017) · Blood · doi:10.1182/blood-2017-06-788786 · Cited by 523
Self-citationExtramedullary disease in multiple myeloma: a systematic literature review
Bladé, J., Beksac, M., Caers, J., Jurczyszyn, A., von Lilienfeld-Toal, M., Moreau, P., Rasche, L., Rosiñol, L., Usmani, S. Z., Zamagni, E., et al. (2022) · Blood Cancer Journal · doi:10.1038/s41408-022-00643-3 · Cited by 319
Self-citation
Metadata
- Authors
- Fernández de Larrea, C., Kyle, R. A., Durie, B. G. M., Ludwig, H., Usmani, S., Vesole, D. H., Hajek, R., San Miguel, J. F., Sezer, O., Sonneveld, P., Kumar, S. K., Mahindra, A., Comenzo, R., Palumbo, A., Mazumber, A., Anderson, K. C., Richardson, P. G., Badros, A. Z., Caers, J., Cavo, M., LeLeu, X., Dimopoulos, M. A., Chim, C. S., Schots, R., Noeul, A., Fantl, D., Mellqvist, U.-H., Landgren, O., Chanan-Khan, A., Moreau, P., Fonseca, R., Merlini, G., Lahuerta, J. J., Bladé, J., Orlowski, R. Z., Shah, J. J., & on behalf of the International Myeloma Working Group
- Venue
- Leukemia
- Published
- 2012-11-21
- Volume
- 27
- Issue
- 4
- Pages
- 780-791
- ISSN
- 0887-6924 (ISSN-L)
- 1476-5551
- OpenAlex
- W2002324468
- Cited by
- 382
- References
- 54
- FWCI
- 10.37
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.